AbbVie (NYSE: ABBV) is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira’s patent cliff are behind it, with Skyrizi, Rinvoq, and the diversified portfolio of products gaining traction. Among the critical details from Q4 and the end of F2024 is that Humira sales are down by solid double-digits and are expected to weaken in 2025. Still, Rinvoq and Skyrizi are up 46% and 58%, respectively, more than offsetting the contraction.
Looking forward, the company has reaffirmed the outlook for a high-single-digit CAGR for at least the next four years, an outlook that puts this high-yielding diamond at under 10x earnings by 2030, a deep value opportunity too good to pass up.
